1-3 of 3
Heather K Webb, Ph.D.
Close
Sort by
Journal Articles

CAL-101, An Isoform-Selective Inhibitor of Phosphatidylinositol 3-Kinase P110δ, Demonstrates Clinical Activity and Pharmacodynamic Effects In Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia

Richard R. Furman, MD, John C. Byrd, MD, Jennifer R Brown, MD, PhD, Steven E. Coutre, MD, Don M Benson, Jr., MD, Nina D. Wagner-Johnston, Ian W. Flinn, MD, PhD, Brad S. Kahl, MD, Stephen E. Spurgeon, MD, Brian Lannutti, PhD, Neil A. Giese, Ph.D., Heather K Webb, Ph.D., Roger G Ulrich, Ph.D., Sissy Peterman, Leanne M. Holes, Albert S Yu, MD
Journal: Blood
Blood (2010) 116 (21): 55.
https://doi.org/10.1182/blood.V116.21.55.55
Published: 2010
Journal Articles

Clinical Pharmacokinetics of CAL-101, a p110δ Isoform-Selective PI3K Inhibitor, Following Single- and Multiple-Dose Administration In Healthy Volunteers and Patients with Hematological Malignancies

Heather K Webb, Ph.D., Hao Chen, Ph.D., Albert S Yu, M.D., Sissy Peterman, Leanne Holes, Brian Lannutti, PhD, Langdon L. Miller, MD, Roger G Ulrich, Ph.D.
Journal: Blood
Blood (2010) 116 (21): 1774.
https://doi.org/10.1182/blood.V116.21.1774.1774
Published: 2010
Journal Articles

Clinical Safety and Activity In a Phase 1 Study of CAL-101, An Isoform-Selective Inhibitor of Phosphatidylinositol 3-Kinase P110δ, In Patients with Relapsed or Refractory Non-Hodgkin Lymphoma

Brad Kahl, MD, John C. Byrd, MD, Ian W. Flinn, MD, PhD, Nina Wagner-Johnston, MD, Stephen Spurgeon, MD, Don M Benson, Jr, MD, Richard R. Furman, MD, Jennifer R Brown, MD, PhD, Steven Coutre, MD, Brian Lannutti, PhD, Neil A. Giese, Ph.D., Roger G Ulrich, Ph.D., Heather K Webb, Ph.D., Sissy Peterman, Leanne Holes, Albert S Yu, MD
Journal: Blood
Blood (2010) 116 (21): 1777.
https://doi.org/10.1182/blood.V116.21.1777.1777
Published: 2010